Skip to main content
Equibles

Jay Duker

COO

EyePoint, Inc. (EYPT)

CEO

EyePoint, Inc. (EYPT)

Board Member

EyePoint, Inc. (EYPT)

Equibles does not estimate personal net worth.

Get an email with a short summary when EyePoint, Inc. publishes a filing, an earnings call transcript or a press release.

Get EYPT alerts

About Jay Duker

Jay Duker is recorded as Board Member at EyePoint, Inc. (EYPT) since January 1, 2016 and COO and CEO at EyePoint, Inc. (EYPT). The newest filing on record that lists Jay Duker as CEO and Board Member at EyePoint, Inc. (EYPT) is dated April 27, 2026. The newest filing on record that lists Jay Duker as COO at EyePoint, Inc. (EYPT) is dated April 28, 2023. The proxy statement of EyePoint, Inc. reports total compensation of $5,568,352 for Jay Duker in fiscal 2025, including a base salary of $696,251. Disclosed compensation is on record for 5 fiscal years. Jay Duker has spoken on 3 investor events across 1 company, most recently for EyePoint, Inc. on September 15, 2026. EyePoint, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at EyePoint, Inc. includes Jay S. Duker (CEO and Board Member), Jay S. Duker, M.D. (CEO, COO and Board Member), Nancy S. Lurker (Chairman and Board Member) and 7 others.

Jay Duker on recent calls

“So the Lugano trial was a phase three trial which studied our virulinib intravitreal insert, 2.7 milligrams per dose. Virulinib is a small molecule tyrosine kinase inhibitor that has activity against all the VEGF receptors, PDGF, and JAK1.”
CEO, Morgan Stanley Global Healthcare Conference ·
“So at iPoint, we are a company that specializes in drug delivery to the back of the eye. Our lead product is called DuraVue. It is the virulinib intraventrial insert.”
CEO, Citi 2026 Biopharma Back to School Conference ·
“So, Lisa, big picture, things could not be going better right now. As you mentioned, our lead asset is called DuraVue. It's a small molecule tyrosine kinase inhibitor called virolinib, which is in our DuraCert-E formulation.”
CEO, RBC Capital Markets Virtual Ophthalmology Conference ·

Affiliation history

Company network

Leadership on record at EyePoint, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 EyePoint, Inc. (EYPT) $696,251 $5,568,352
2024 EyePoint, Inc. (EYPT) $669,500 $5,954,807
2023 EyePoint, Inc. (EYPT) $614,064 $2,915,146
2022 EyePoint, Inc. (EYPT) $515,000 $2,063,438
2021 EyePoint, Inc. (EYPT) $268,667 $3,314,080

Recent activity